Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (11032)	2/9/2017 1:05:10 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

>> since the stock has almost four bagged off of lows << And at those lows, B.J. was in the valuation thread, pounding table for buy. GREAT call, Jim. I did not invest. I sold low, taking a large loss, after the high dose was eliminated from testing. Tuck, I'll again take a look at pirs. Beta emitters, linked to MAbs... not exactly a new concept. Guess there could be a major bennie, given new targeting.

To: tuck who wrote (11032)	2/22/2017 7:55:06 AM
From: Biotech Jim	Read Replies (1) \| Respond to of 12215

<Do you or anyone else have thoughts on 845"s launch performance?> I did not realize that CR845 has launched.. Joking aside, I think CARA would sell the company rather than launch the drug itself if it gets that far, ie 'commercially' approvable. JNJ in my view would be the primary bidder, but others of course would be interested. Also depends on pruritis vs iv pain vs oral pain applications. The IV CR845 potential launch for pruritis could be relatively straightforward for CARA to go alone in the US. For any pain commercialization, one would want a corporate marketing effort and a detail group. Then there is exUS. On my CARA holdings, I sold a few shares recently, and II will sell more shares on news flow, in fact some shares are teed up now. Its been a long haul. I am working the plan now.